

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7733095

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CADENT THERAPEUTICS, INC.	12/01/2022
RECEIVING PARTY DATA	
Name:	NOVARTIS AG
Street Address:	LICHSTRASSE 35
City:	BASEL
State/Country:	SWITZERLAND
Postal Code:	4056
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	9340544
CORRESPONDENCE DATA	
Fax Number:	(215)568-3439
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2155683100
Email:	assignments@bakerlaw.com
Correspondent Name:	BAKER HOSTETLER LLP
Address Line 1:	1735 MARKET STREET
Address Line 2:	SUITE 3300
Address Line 4:	PHILADELPHIA, PENNSYLVANIA 19103-7501
ATTORNEY DOCKET NUMBER:	105728.000012
NAME OF SUBMITTER:	VALERIE CHICCHI
SIGNATURE:	/Valerie Chicchi/
DATE SIGNED:	01/10/2023
Total Attachments: 6	
source=ASSIGNMENT_CADENT_TO_NOVARTIS_9340544#page1.tif	
source=ASSIGNMENT_CADENT_TO_NOVARTIS_9340544#page2.tif	
source=ASSIGNMENT_CADENT_TO_NOVARTIS_9340544#page3.tif	
source=ASSIGNMENT_CADENT_TO_NOVARTIS_9340544#page4.tif	
source=ASSIGNMENT_CADENT_TO_NOVARTIS_9340544#page5.tif	

ASSIGNMENT

This Assignment Agreement is entered into by and between **CADENT THERAPEUTICS, Inc.**, One Health Plaza, East Hanover, New Jersey, 07936, United States of America; a company organized under the laws of Delaware; and **NOVARTIS AG**, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, **CADENT THERAPEUTICS, Inc.** confirms that **CADENT THERAPEUTICS, Inc.**, has sold, assigned, and transferred, and does hereby sell, assign and transfer to **NOVARTIS AG** and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) in the attached Schedule

SEE ATTACHED SCHEDULE

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and

divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by **CADENT THERAPEUTICS, Inc.**, if this sale, assignment and transfer had not been made.

CADENT THERAPEUTICS, Inc., hereby authorizes ASSIGNEE and their representatives to insert in the Schedule of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

CADENT THERAPEUTICS, Inc., hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE .

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect.


The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.


This Assignment shall be governed by the laws of Switzerland.


This Assignment is effective as from the earliest priority date as stated in the Schedule.

Executed this 10th day of December, 2022.

CADENT THERAPEUTICS, Inc.,


BY 
Printed Name: Eduard Marti
Authorized Signatory


Witness: 
Printed Name: JANE OGILVIE
City, State and Country: East Hanover, NJ, USA


Witness: 
Printed Name: LUCIA LUZZI
City, State and Country: East Hanover, NJ, USA

Executed this 6 day of Dec, 2022.


NOVARTIS AG


BY 
Printed Name: Dr. Charlotte Retzler
Authorized Signatory Authorized Signatory


Witness: 
Printed Name: Cecile De Lavallaz
City, State and Country: Lichtstrasse 35
CH-4056 Basel

Witness: 
Printed Name: Sudeshna Patekar
City, State and Country: Lichtstrasse 35
4056 Basel
Switzerland

NOVARTIS AG

BY 
Printed Name: Ian James Hiscock
Authorized Signatory Authorized Signatory

Witness: 
Printed Name: Cecile De Lavallaz
City, State and Country: Lichtstrasse 35
CH-4056 Basel

Witness: 
Printed Name: Sudeshna Patekar
City, State and Country: Lichtstrasse 35
4056 Basel
Switzerland

SCHEDULE

PAT059132					
Case Reference	Country	Filing Date	Filing Number	Publication Number	Grant Number
PAT059132-AU-PCT	AU	03/27/2008	2008231695	2008231695	2008231695
PAT059132-BR-PCT	BR	03/27/2008	PI 0808746-6	PI0808746	PI0808746-6
PAT059132-CA-PCT	CA	03/27/2008	2682019	2682019	2,682,019
PAT059132-CN-PCT	CN	03/27/2008	200880009964.5	101646669	101646669
PAT059132-DE-EPT	DE	03/27/2008	602008050566.9	2142546	2142546
PAT059132-DE-ETD	DE	3/27/2008	602008052712.3	2402341	2402341
PAT059132-DK-NP	DK	3/28/2007	PA 2007 00482		
PAT059132-EP-EPT	EP	03/27/2008	08718278.8	2142546	2142546
PAT059132-EP-ETD	EP	03/27/2008	11182703.6	2402341	2402341
PAT059132-FR-EPT	FR	03/27/2008	08718278.8	2142546	2142546
PAT059132-FR-ETD	FR	3/27/2008	11182703.6	2402341	2402341
PAT059132-GB-EPT	GB	03/27/2008	08718278.8	2142546	2142546
PAT059132-GB-ETD	GB	3/27/2008	11182703.6	2402341	2402341
PAT059132-HK-FPR	HK	9/24/2009	10107002.9	1141008	1141008
PAT059132-IL-PCT	IL	03/27/2008	200501	200501	
PAT059132-IN-PCT	IN	03/27/2008	5654/CHENP/2009	5654/CHENP/2009	IN303751
PAT059132-JP-PCT	JP	03/27/2008	2010-500272	2010522718	5703432
PAT059132-KR-PCT	KR	03/27/2008	10-2009-7020281	1020100014648	10-1564233
PAT059132-MX-PCT	MX	03/27/2008	MX/a/2009/010122		307537
PAT059132-NZ-PCT	NZ	03/27/2008	579248	579248	579248
PAT059132-RU-PCT	RU	03/27/2008	2009132881	2009132881	2468026
PAT059132-SG-PCT	SG	03/27/2008	2009 05573-2	154863	154863
PAT059132-AE-PCT	AE	03/27/2008	a200908793		98482

PAT059132- US-PSP	US	3/28/2007	60/908,503		
PAT059132- US-PCT	US	03/27/2008	12/593194	US 2010-0120797 A1	8,362,024
PAT059132- US-CNT	US	03/27/2008	13/720956	US 2013-0109704 A1	9,340,544
PAT059132- WO-PCT	WO	03/27/2008	PCT/EP2008/053648	WO/2008/116909	
PAT059132- ZA-PCT	ZA	03/27/2008	2009/05796	2009/05796	2009/05796